TELA · TELA Bio, Inc. · Earnings Call Transcripts & Audio
$1.15
-0.09 (-7.26%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. Accordingly, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Aug 11, 2026
Market Cap
$56.57M
Shares
44.89M
Volume · Sep 30
94K
Avg daily vol (3M)
202.38K
TELA Bio, Inc. Earnings Call Transcripts
Quarterly earnings calls for TELA Bio, Inc. (TELA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲45.8%
$11.16M
−$10.71M
'22 Q3
22-11-09
▲38.8%
$11.62M
−$9.98M
'22 Q4
23-03-21
▲44.7%
$11.91M
−$12.03M
'23 Q1
23-04-18
▲39.3%
$14.49M
−$10.79M
'23 Q2
23-08-09
▲34.9%
$15.05M
−$10.96M
'23 Q3
23-11-09
▲46.3%
$17.00M
−$12.89M
'23 Q4
24-03-21
▲39.4%
$16.60M
−$5.66M
'24 Q1
24-05-09
▲11%
$16.09M
−$12.60M
'24 Q2
24-08-12
▲25.9%
$18.96M
−$10.37M
'24 Q3
24-11-07
▲3.8%
$17.65M
−$9.21M
'24 Q4
25-03-20
▲11.5%
$18.52M
−$11.26M
'25 Q1
25-05-08
▲25.5%
$20.20M
−$9.92M
'25 Q2
25-08-11
▲9.1%
$20.69M
−$8.60M
'25 Q3
25-11-13
▲18.2%
$20.87M
−$9.04M
'25 Q4
26-03-24
▲2.9%
$19.06M
−$12.27M
'26 Q1
26-05-12
LATEST
▼4.5%
$19.29M
−$11.26M
'26 Q2
26-08-10
Earnings call
FY26 · Q2
2026-08-10
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call
Revenue
$19.29M
▼ 4.5% YoY Diluted EPS
$-0.20
Gross margin
72.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
TELA Bio, Inc. (TELA) Q1 2026 Earnings Call Transcript
Confident tone
Ovatex LTR product launch
Board of directors refresh
Second half 2026 outlook and guidance skew
Revenue
$19.06M
▲ 2.9% YoY Diluted EPS
$-0.21
Gross margin
65.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
TELA Bio, Inc. (TELA) Q4 2025 Earnings Call Transcript
Positive tone
Product Portfolio and Innovation
Clinical Pipeline
Commercial Organization Rebuild
Revenue
$20.87M*
▲ 18.2% YoY Gross margin
65.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-13
TELA Bio, Inc. (TELA) Q3 2025 Earnings Call Transcript
Positive tone
Revenue growth and commercial milestones
Sales force build-out and productivity
Liquidity and balance sheet
Revenue
$20.69M
▲ 9.1% YoY Diluted EPS
$-0.19
Gross margin
67.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
TELA Bio, Inc. (TELA) Q2 2025 Earnings Call Transcript
Confident tone
Revenue milestone and growth
Portfolio transition from niche to broad hernia provider
New leadership and execution
Revenue
$20.20M
▲ 25.5% YoY Diluted EPS
$-0.22
Gross margin
69.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
TELA Bio, Inc. (TELA) Q1 2025 Earnings Call Transcript
Positive tone
Revenue growth and guidance
Tariff exposure and gross margin
Commercial organization expansion
Revenue
$18.52M
▲ 11.5% YoY Diluted EPS
$-0.25
Gross margin
67.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript
Cautious tone
Sales force turnover and realignment
Product portfolio and market opportunity (OviTex)
Commercial strategy: TM/AS team structure
Revenue
$17.65M*
▲ 3.8% YoY Gross margin
63.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript
Confident tone
Quarterly revenue growth and product momentum
2025 outlook and guidance
International/European expansion
Revenue
$18.96M
▲ 25.9% YoY Diluted EPS
$-0.42
Gross margin
67.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript
Positive tone
Q2 revenue growth and headwinds
OviTex and LIQUIFIX product portfolio
Path to profitability and OpEx discipline
Revenue
$16.09M
▲ 11% YoY Diluted EPS
$-0.51
Gross margin
68.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
TELA Bio, Inc. (TELA) Q1 2024 Earnings Call Transcript
Confident tone
GPO and IDN Contracts
LIQUIFIX Product Suite
OviTex PRS / Plastic and Reconstructive Surgery
Revenue
$16.60M
▲ 39.4% YoY Diluted EPS
$-0.23
Gross margin
68.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
Confident tone
Product Portfolio Expansion (LIQUIFIX and OviTex IHR)
GPO Contracts and Hospital Adoption
Operating Losses and Cash Burn
Revenue
$17.00M*
▲ 46.3% YoY Gross margin
68.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
TELA Bio, Inc. (TELA) Q3 2023 Earnings Call Transcript
Revenue
$15.05M
▲ 34.9% YoY Diluted EPS
$-0.45
Gross margin
69.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
TELA Bio, Inc. (TELA) Q2 2023 Earnings Call Transcript
Revenue
$14.49M
▲ 39.3% YoY Diluted EPS
$-0.46
Gross margin
70.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-18
TELA Bio, Inc. (TELA) Q1 2023 Earnings Call Transcript
Revenue
$11.91M
▲ 44.7% YoY Diluted EPS
$-0.63
Gross margin
66.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-21
TELA Bio, Inc. (TELA) Q4 2022 Earnings Call Transcript
Revenue
$11.62M*
▲ 38.8% YoY Gross margin
70.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
TELA Bio, Inc. (TELA) Q3 2022 Earnings Call Transcript
Revenue
$11.16M
▲ 45.8% YoY Diluted EPS
$-0.64
Gross margin
65.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
TELA Bio, Inc. (TELA) Q2 2022 Earnings Call Transcript
Revenue
$10.41M
▲ 37.7% YoY Diluted EPS
$-0.88
Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
TELA Bio, Inc. (TELA) Q1 2022 Earnings Call Transcript
Revenue
$8.23M
▲ 40.1% YoY Diluted EPS
$-0.75
Gross margin
60.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-21
TELA Bio, Inc. (TELA) Q4 2021 Earnings Call Transcript
Revenue
$8.37M*
▲ 47.8% YoY Gross margin
67.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
TELA Bio, Inc. (TELA) Q3 2021 Earnings Call Transcript
Revenue
$7.65M
▲ 44.1% YoY Diluted EPS
$-0.57
Gross margin
60.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
TELA Bio, Inc. (TELA) Q2 2021 Earnings Call Transcript
Revenue
$7.56M
▲ 115.5% YoY Diluted EPS
$-0.57
Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
TELA Bio, Inc. (TELA) Q1 2021 Earnings Call Transcript
Revenue
$5.88M
▲ 57.7% YoY Diluted EPS
$-0.56
Gross margin
59.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-24
TELA Bio, Inc. (TELA) Q4 2020 Earnings Call Transcript
Revenue
$5.67M*
▲ 16.5% YoY Gross margin
64.6%
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-12
TELA Bio, Inc. (TELA) Q3 2020 Earnings Call Transcript
Revenue
$5.31M
▲ 33.7% YoY Gross margin
61.9%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-12
TELA Bio, Inc. (TELA) Q2 2020 Earnings Call Transcript
Revenue
$3.51M
▲ 6.2% YoY Gross margin
59.5%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
TELA Bio, Inc. (TELA) Q1 2020 Earnings Call Transcript
Revenue
$3.73M
▲ 12.7% YoY Gross margin
59.0%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-10
TELA Bio, Inc. (TELA) Q4 2019 Earnings Call
Revenue
$4.86M*
Gross margin
60.9%
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls